Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma - Trial NCT01026493
Access comprehensive clinical trial information for NCT01026493 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Radiation Therapy Oncology Group and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 257 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Radiation Therapy Oncology Group
Timeline & Enrollment
Early Phase 1
Jul 01, 2010
Dec 01, 2016
Primary Outcome
Phase 1: Maximum Tolerated Dose (MTD),Phase II: 6-month Progression-free Survival (PFS) Rate for Patients With Measurable Disease After Surgery
Summary
RATIONALE: Veliparib may stop the growth of tumor cells by blocking some of the enzymes
 needed for cell growth. Drugs used in chemotherapy, such as temozolomide. work in different
 ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
 dividing. Giving veliparib together with temozolomide may kill more tumor cells.
 
 PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of
 giving veliparib together with temozolomide and to see how well it works in treating patients
 with recurrent glioblastoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01026493
Non-Device Trial